Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Lupin Pharmaceuticals

X
Drug Profile

Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Lupin Pharmaceuticals

Alternative Names: TDF/3TC/DTG - Lupin Pharmaceuticals; Tenofovir disoproxil fumarate/dolutegravir/lamivudine - Lupin Pharmaceuticals; Tenofovir disoproxil fumarate/lamivudine/dolutegravir - Lupin Pharmaceuticals; TLD - Lupin Pharmaceuticals

Latest Information Update: 16 Jul 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lupin Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered HIV-1 infections

Most Recent Events

  • 09 Jul 2021 Chemical structure information added
  • 25 Jun 2021 Registered for HIV-1 infections (In adolescents, In children, In adults) in USA (PO) - tentative approval under the US President’s Emergency Plan for AIDS Relief (PEPFAR)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top